Last reviewed · How we verify
Tears Naturale II Ophthalmic Solution
Tears Naturale II is an artificial tear solution that lubricates and protects the ocular surface by mimicking natural tear composition.
Tears Naturale II is an artificial tear solution that lubricates and protects the ocular surface by mimicking natural tear composition. Used for Dry eye syndrome / Keratoconjunctivitis sicca, Temporary relief of ocular irritation and discomfort.
At a glance
| Generic name | Tears Naturale II Ophthalmic Solution |
|---|---|
| Sponsor | ORA, Inc. |
| Drug class | Artificial tear / Lubricating ophthalmic solution |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This ophthalmic solution contains a combination of lubricants (hypromellose and dextran 70) and electrolytes designed to replicate the protective and moisturizing properties of natural tears. It provides temporary relief of dry eye symptoms by coating the cornea and conjunctiva, reducing friction and maintaining ocular surface hydration.
Approved indications
- Dry eye syndrome / Keratoconjunctivitis sicca
- Temporary relief of ocular irritation and discomfort
Common side effects
- Transient blurred vision
- Eye irritation or stinging
- Allergic reaction (rare)
Key clinical trials
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease (NA)
- Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD (NA)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tears Naturale II Ophthalmic Solution CI brief — competitive landscape report
- Tears Naturale II Ophthalmic Solution updates RSS · CI watch RSS
- ORA, Inc. portfolio CI